Sickle Cell

MGH gives grant to low-cost sickle cell diagnostic

Mar 31, 2015 Jessica Bartlett Reporter-Boston Business Journal Massachusetts General Hospital’s Center for Global Health is helping to fund an affordable sickle cell diagnostic, awarding $100,000 to the Whitesides Research Group. Courtesy/Whitesides Research Group A density test can tell whether someone has sickle cell disease. The team, led by Harvard University Chemistry Professor George Whitesides, has been working

Sickle Cell Drug Offers “Overwhelming” Gains as “Exciting” Stem Cell Trial Starts

Mon, 03/16/2015 - 3:58pm Cynthia Fox, Science Editor Normal blood cells next to a sickle-blood cell, colored scanning electron microscope image (Credit: OpenStax College)A clinical trial of the most common sickle cell anemia drug, hydroxyurea, was halted a year early this winter because of “overwhelming evidence of benefit,” reported University of Nebraska Medical Center pediatric

Johns Hopkins researchers engineer custom blood cells

Step toward new treatment for patients with sickle cell disease March 9, 2015 JOHNS HOPKINS MEDICINE Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report. The study represents an important step toward

Investigational Therapy Could Attack Cause of Sickle Cell Crises

Mar. 2, 2015 By Duke Medicine News and Communications DURHAM, N.C. – Treatment for painful episodes of blood vessel obstruction in sickle cell anemia is currently limited to controlling pain, but an investigational therapy might be able to interfere with the underlying cause of these events, known as vaso-occlusion crises, researchers at Duke Medicine report.

Successful Outcome Brings Early End To TWITCH Sickle Cell Anemia Clinical Trial

BioNews Texas, by Charles Moore ~ December 1, 2014 Sickle cell anemia is the most common form of sickle cell disease among a group of inherited red blood cell disorders and the most common genetic disease in the U.S., afflicting an estimated 70,000-80,000 Americans according to the William E. Proudford Sickle Cell Fund Inc. Normal

Monthly transfusions reduce strokes in children with sickle cell anemia

Washington University in St. Louis, by Michael C. Purdy ~ August 20, 2014 Monthly blood transfusions reduce the risk of stroke in young patients with sickle cell anemia, scientists report Aug. 20 in The New England Journal of Medicine. An estimated 1 in 3 children with sickle cell anemia experiences silent strokes — loss of

Stem Cell Transplant Reverses Sickle Cell Disease in Adults

National Institutes of Health, by Staff ~ July 14, 2014 Sickle cell disease is an inherited blood disorder that affects more than 90,000 Americans, mostly of African descent. The condition arises from a genetic defect that alters the structure of hemoglobin, the oxygen-carrying protein found in red blood cells. The modified hemoglobin causes normally round

Marrow Transplants Can Reverse Adult Sickle Cell

Bioscience Technology, by Lindsey Tanner ~ July 1, 2014 Bone marrow transplants can reverse severe sickle cell disease in adults, a small study by government scientists found, echoing results seen with a similar technique used in children. The researchers and others say the findings show age need not be a barrier and that the technique

SLU Researchers Study Therapy to Relieve Sickle Cell Pain

Newswise, by Staff ~ 1/22/14 Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease. “Sickle cell crises, which are acute episodes that can land patients in the

Studies uncover new insights into pathophysiology of sickle cell disease and thalassemia, may help improve standard of care

Medical News Today, by Staff ~ December 11, 2013 New research presented during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncovers several important insights into the pathophysiology of sickle cell disease and thalassemia that may soon translate into the development of better, more targeted treatments for hundreds of thousands